Old Web
English
Sign In
Acemap
>
authorDetail
>
J.T. OMalley
J.T. OMalley
Dupilumab
Dermatology
Medicine
Baseline weight
Immunology
3
Papers
6
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
434 The study design of two trials of dupilumab in patients with prurigo nodularis inadequately controlled with topical therapies: LIBERTY PN PRIME and PRIME 2
2021
Journal of Investigative Dermatology
Gil Yosipovitch
Nicholas K. Mollanazar
Sonja Ständer
Shawn G. Kwatra
J. Luo
N. Amin
L.P. Mannent
E. Laws
Ashish Bansal
J.T. OMalley
Show All
Source
Cite
Save
Citations (0)
Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study
2020
British Journal of Dermatology
Michael J. Cork
Diamant Thaçi
Lawrence F. Eichenfield
Peter D. Arkwright
X. Sun
Zhen Chen
Bolanle Akinlade
Susan Boklage
I. Guillemin
M.P. Kosloski
M. A. Kamal
J.T. OMalley
N. Patel
N.M.H. Graham
Ashish Bansal
Show All
Source
Cite
Save
Citations (6)
LB941 Dupilumab for atopic dermatitis in children aged ≥6 to <12 years in phase 3 LIBERTY AD PEDS trial: Analysis by baseline weight
2020
Journal of Investigative Dermatology
Amy S. Paller
Elaine C. Siegfried
Lisa A. Beck
J.T. OMalley
B. Shumel
Show All
Source
Cite
Save
Citations (0)
1